Vericel (VCEL) to Release Earnings on Thursday

Vericel (NASDAQ:VCEL) is projected to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $0.31 per share and revenue of $76.47 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Vericel Stock Performance

Shares of VCEL stock opened at $52.33 on Tuesday. Vericel has a fifty-two week low of $39.12 and a fifty-two week high of $63.00. The stock’s fifty day moving average is $57.56 and its two-hundred day moving average is $51.70. The firm has a market capitalization of $2.58 billion, a P/E ratio of 872.31 and a beta of 1.72.

Insider Transactions at Vericel

In other news, insider Jonathan Mark Hopper sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $58.72, for a total transaction of $587,200.00. Following the completion of the transaction, the insider now directly owns 58,371 shares in the company, valued at approximately $3,427,545.12. This represents a 14.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the sale, the director now owns 26,595 shares in the company, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,100 shares of company stock worth $1,206,072 in the last 90 days. Insiders own 5.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on VCEL shares. BTIG Research raised their price target on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a report on Wednesday, January 15th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. Truist Financial upped their price target on Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, Canaccord Genuity Group lifted their price objective on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Vericel has an average rating of “Moderate Buy” and an average price target of $63.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.